Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 4/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444608 | 1.00 | SRC (0.40) | SRCKDM4EUSP2ALDH1A1EGFR | |
| SCHEMBL30445142 | 0.77 | S1PR2 (0.35) | SRCKDM4EALDH1A1AR | |
| SCHEMBL20168401 | 0.77 | S1PR2 (0.35) | SRCKDM4EALDH1A1AR | |
| SCHEMBL19565811 | 0.77 | AR (0.44) | SRCKDM4EUSP2ALDH1A1EGFR | |
| SCHEMBL16668884 | 0.75 | KDM4E (0.49) | SRCKDM4EUSP2ALDH1A1EGFR | |
| SCHEMBL7875292 | 0.75 | MAP2K1 (0.44) | SRCKDM4EUSP2ALDH1A1EGFR | |
| SCHEMBL286435 | 0.75 | SRC (0.45) | SRCKDM4EUSP2ALDH1A1EGFR | |
| SCHEMBL20168375 | 0.75 | EGFR (0.44) | SRCKDM4EUSP2ALDH1A1EGFR | |
| SCHEMBL30225338 | 0.74 | ALDH1A1 (0.34) | KDM4EALDH1A1P2RX3P2RX2 | |
| SCHEMBL21266215 | 0.74 | SRC (0.40) | SRCKDM4EUSP2ALDH1A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| CN-110678463-B | Substituted nitrogen-containing compounds | 百时美施贵宝公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3630752-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
| CN-110678463-A | Substituted nitrogen-containing compounds | 百时美施贵宝公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3535258-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| US-20180346453-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-12-06 | — | — | US | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SRC 1665/4885KDM4E 3111/4885USP2 4762/4885 |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SRC 1665/4885KDM4E 3111/4885USP2 4762/4885 |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | SRC 1676/4885KDM4E 3724/4885USP2 4744/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | SRC 1676/4885KDM4E 3724/4885USP2 4744/4885 |
| US-20180346453-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SRC 1665/4885KDM4E 3111/4885USP2 4762/4885 |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SRC 1665/4885KDM4E 3111/4885USP2 4762/4885 |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SRC 1665/4885KDM4E 3111/4885USP2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.